![]() ![]() Participants will undergo eight weeks of treatment with MORE therapy plus two KAP sessions at Novamind's Murray, Utah research site in early 2022.ĭr. The hope is that ketamine will enhance the benefits of buprenorphine for this difficult-to-treat condition when paired with MORE, a proven psychological intervention developed by Dr. The MORE+KAP Clinical Trial, led by lead investigator Eric Garland, PhD, LCSW at the University of Utah, is the first to investigate the effects of intramuscular KAP for adult outpatients treated with buprenorphine, a first-line medication for opioid use disorder. Recent studies have shown promise for the use of ketamine in treating substance use disorders, including alcohol and cocaine use disorders.1,2 With opioid-related deaths continuing to rise across nearly all populations age 15 and older,3the MORE+KAP Clinical Trial comes at a critical time and makes an important contribution to the early evidence base for effective treatment options. The study will investigate the safety and efficacy of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement therapy (the "MORE+KAP Clinical Trial"). (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it will host a phase I randomized clinical trial for adults with opioid use disorder. The SLC Clinic is located at 807 E South Temple, Suite 101, Salt Lake City, Utah.TORONTO, ON / ACCESSWIRE / Janu/ Novamind Inc. Additionally, the SLC Clinic will pilot an innovative and cost-effective group medical visit model that has been shown to reduce anxiety and depression, as well as improve outcomes in chronic conditions like cardiovascular disease and diabetes. Novamind will collect clinical data on the efficacy of the integrative treatment approach for SUD and host upcoming studies for conditions like opioid use disorder. de la Garza, who is also trained in integrative modalities and lifestyle medicine, including nutrition, movement, sleep, stress management, and social connection. "I am thrilled to join Novamind and look forward to establishing an innovative outpatient substance use disorder program that brings together addiction and integrative medicine and treats the whole person," said Dr. de la Garza opened the first community-based, co-located primary care and behavioral health practice in Salt Lake City, Utah. She also completed an Addiction Medicine Fellowship at the University of Utah and is an Institute for Functional Medicine Certified Practitioner. She earned her Doctorate in Medicine from the University of Colorado before completing a Family Medicine Residency at the Utah Healthcare Institute. de la Garza is a board-certified family practice physician with 10 years of experience providing specialized care for patients with behavioral health and SUD diagnoses. de la Garza's expertise in addiction medicine and behavioural health is a vital addition to our team as we continue to expand Novamind's clinic footprint to address unmet need and broaden our innovative, evidence-based treatments."ĭr. ![]() ![]() Reid Robison, Novamind's Chief Medical Officer, commented: "Social isolation and despair related to the COVID-19 pandemic have further fueled a significant increase in substance use disorders and related deaths. In 2020 alone, 93,000 Americans died of a drug overdose-an increase of 30 percent from the previous year, according to the Centers for Disease Control and Prevention.ĭr. The SLC Clinic's outpatient SUD services provide an alternative to residential treatment programs and work to address the highly complex public health crisis that is worsening alongside challenges related to access. READ ALSO: Addiction Recovery and Holistic Medicine - Dr.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |